Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling.

ABSTRACT:

Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by declines in cognitive and functional severities. This research utilized the Clinical Dementia Rating (CDR) to assess the influence of tilavonemab on these deteriorations.

Methods

Longitudinal Item Response Theory (IRT) models were employed to analyze CDR domains in early-stage AD patients. Both unidimensional and multidimensional models were contrasted to elucidate the trajectories of cognitive and functional severities.

Results

We observed significant temporal increases in both cognitive and functional severities, with the cognitive severity deteriorating at a quicker rate. Tilavonemab did not demonstrate a statistically significant effect on the progression in either severity. Fur

SUBMITTER: Zhou X 

PROVIDER: S-EPMC11148533 | biostudies-literature | 2024 Apr-Jun

REPOSITORIES: biostudies-literature